Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: High Cardiovascular Risk Clear all
Terminated No phase listed Observational

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke

NCT05421533
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Fullerton, California • Boca Raton, Florida • Homestead, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

NCT00531843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
fondaparinux sodium, sequential compression devices
Drug · Device
Lead sponsor
Mary Knudson, M.D.
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 25, 2026, 4:13 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of Diet Composition on Weight Change and Metabolic Parameters

NCT01642849
View directory record Official record
Conditions
Obesity, Inflammation
Interventions
high protein diet, high carbohydrate diet
Dietary Supplement
Lead sponsor
University of Tennessee
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

NCT03601078
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bb2121, Lenalomide, Talquetamab
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
18
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides

NCT00728338
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Docosahexenoic acid (DHA), Olive oil
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
39 Years to 66 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional

Randomized Trial to Evaluate the Effectiveness of Nurse Case Management

NCT00295256
View directory record Official record
Conditions
Type 2 Diabetes, Gestational Diabetes, Hypertension, Preterm Delivery
Interventions
nurse case manager
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE

NCT00577512
View directory record Official record
Conditions
Multiple Myeloma
Interventions
DTPACE
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 25, 2026, 4:13 AM EDT
Completed No phase listed Observational

Accuracy of the D-Dimer Assay for the Exclusion of Pulmonary Embolism in a High Risk Oncologic Population

NCT00615147
View directory record Official record
Conditions
Cancer, Pulmonary Embolism
Interventions
CT pulmonary angiogram and d-dimer draw
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2012 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting Not applicable Interventional

The Half Moon Transcatheter Mitral Valve Repair (TMVr) Pilot Study

NCT04343313
View directory record Official record
Conditions
Mitral Valve Insufficiency
Interventions
Half Moon TMVr System
Device
Lead sponsor
Half Moon Medical
Industry
Eligibility
21 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
New York, New York • The Bronx, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 25, 2026, 4:13 AM EDT
Terminated No phase listed Observational

Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

NCT05819125
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
21,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional Results available

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk

NCT01314313
View directory record Official record
Conditions
Symptomatic Severe Aortic Stenosis
Interventions
TAVR Implantation with SAPIEN XT, SAVR Implantation
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
2,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
55
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 25, 2026, 4:13 AM EDT
Withdrawn Not applicable Interventional

Contrast Enhanced Ultrasound Endoleak Identification and Classification

NCT04615559
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
Contrast enhanced ultrasound
Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 25, 2026, 4:13 AM EDT
Active, not recruiting Phase 1 Interventional

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

NCT01815749
View directory record Official record
Conditions
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
Biological · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional

Electronic Alerts for Stroke Prevention in Atrial Fibrillation

NCT02958943
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
On-screen electronic alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 25, 2026, 4:13 AM EDT
Completed No phase listed Observational

SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy

NCT00403078
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
Not listed
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
21,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
5
States / cities
Newark, Delaware • West Des Moines, Iowa • Lincoln, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Essential Amino Acids and High Intensity Interval Training

NCT04080102
View directory record Official record
Conditions
Cardiovascular Risk Factor, Obesity
Interventions
High Intensity Interval Training, Essential Amino Acid, High intensity interval training and essential amino acid supplement
Other · Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Sep 25, 2026, 4:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

NCT02681302
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional

Translating the Diabetes Prevention Program Into a Virtual Lifestyle Management Program

NCT00867425
View directory record Official record
Conditions
Obesity, Diabetes, Cardiovascular Disease
Interventions
Virtual Lifestyle Management
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 62 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Sep 25, 2026, 4:13 AM EDT
Withdrawn Phase 4 Interventional

Predicting Stroke Risk in ICAD With Novel MRI

NCT05515874
View directory record Official record
Conditions
Intracranial Atherosclerosis
Interventions
Feraheme
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Not listed Not applicable Interventional

Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery

NCT02389023
View directory record Official record
Conditions
Peripheral Artery Disease, Critical Limb Ischemia, Claudication
Interventions
standard gauze dressing, Prevena Incision Management system
Other
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Portland, Maine • Boston, Massachusetts • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional Results available

Patient Navigator Intervention for Diabetic Retinopathy

NCT05188703
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Blindness
Interventions
Patient Navigation
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed No phase listed Observational

Risk-score Based ICU Triage

NCT03390270
View directory record Official record
Conditions
Non-ST Elevation Myocardial Infarction (nSTEMI)
Interventions
Admission with NSTEMI
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

NCT02145403
View directory record Official record
Conditions
Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
Interventions
Carfilzomib, Tacrolimus
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

NCT01709513
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Ezetimibe, Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
41
States / cities
Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 25, 2026, 4:13 AM EDT